Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674024 · ClinicalTrials.gov registry record · Phase 1
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00674024: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00674024 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00674024, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Background: * Pazopanib is an experimental drug that was designed to enter cancer cells and block the activity of proteins that are important for cancer cell growth and survival. * This is the first study in which pazopanib is given to patients with different degrees of liver function. The safe dose for patients with normal liver function is already known. Objectives: * To determine the safety and side effects of pazopanib given at different dose levels to patients with cancer who have different degrees of liver function. * To find out how much pazopanib is in the blood at specific times. * To determine if pazopanib is effective in treating advanced cancer in patients with different degrees of liver function. Eligibility: \- Patients 18 years of age and older with an advanced solid tumor or lymphoma that cannot be treated successfully with standard therapies and who have normal or abnormal liver function. Design: * Treatment: * Patients are divided into 4 groups, based on their liver function. The first three patients in each group receive a low dose of pazopanib. The next three in each group receive a higher dose of pazopanib if no serious side effects were reported in the previous three. The dose is increased in succeeding groups of three patients until the maximum study dose is reached. * Patients take pazopanib once a day by mouth in 21-day treatment cycles. Treatment continues until the cancer worsens, the patient develops severe side effects, the patient no longer wants to continue the study, or the doctor removes the patient from the study for other reasons. * Monitoring: * Blood pressure: Patients monitor and record their blood pressure twice a day after starting treatment. * Blood tests: Patients have weekly routine blood tests. In addition, at week 3 of the first cycle and again after the highest safe dose has been determined, several blood samples are collected at frequent intervals to determine how the body handles the drug. * Imaging studies: X-r
Interventions
- DRUG Pazopanib
- DRUG Pazopanib (GW786034)(GW786034)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-10-07 |
| Est. Completion | 2013-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674024
The ClinicalTrials.gov registry entry for NCT00674024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pazopanib is the first listed.
NCT00674024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00674024 about?
NCT00674024 is a clinical study titled "Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function". Background: * Pazopanib is an experimental drug that was designed to enter cancer cells and block the activity of proteins that are important for cancer cell growth and survival. * This is the first study in which pazopanib is given to patients with different degrees of liver function. The safe dos...
What is the current status of trial NCT00674024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2008-10-07. Estimated completion is 2013-01-22.
What interventions are being tested in trial NCT00674024?
The interventions under investigation include: Pazopanib (DRUG), Pazopanib (GW786034)(GW786034) (DRUG).
Who is sponsoring clinical trial NCT00674024?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.